Y Intercept Hong Kong Ltd Acquires New Position in CytomX Therapeutics, Inc. $CTMX

Y Intercept Hong Kong Ltd acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 167,514 shares of the biotechnology company’s stock, valued at approximately $787,000.

Other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $35,000. Goldman Sachs Group Inc. purchased a new position in CytomX Therapeutics during the first quarter worth approximately $39,000. Finally, May Hill Capital LLC purchased a new position in CytomX Therapeutics during the fourth quarter worth approximately $46,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Price Performance

CTMX stock opened at $3.76 on Monday. The business has a fifty day moving average of $3.52 and a two-hundred day moving average of $4.40. The stock has a market cap of $639.91 million, a price-to-earnings ratio of -9.17 and a beta of 2.08. CytomX Therapeutics, Inc. has a 52-week low of $1.72 and a 52-week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%.The company had revenue of $10.26 million for the quarter, compared to the consensus estimate of $4.68 million. As a group, sell-side analysts anticipate that CytomX Therapeutics, Inc. will post -0.45 EPS for the current year.

Analysts Set New Price Targets

CTMX has been the subject of several analyst reports. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $7.00 to $12.00 in a report on Monday, March 16th. Guggenheim boosted their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Wedbush upped their price objective on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday, March 17th. Wall Street Zen upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group raised their price objective on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CytomX Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.10.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.